BR112022010223A2 - Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina que direcionam interleucina 13 (il-13) e linfopoietina estromal tímica (tslp) - Google Patents
Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina que direcionam interleucina 13 (il-13) e linfopoietina estromal tímica (tslp)Info
- Publication number
- BR112022010223A2 BR112022010223A2 BR112022010223A BR112022010223A BR112022010223A2 BR 112022010223 A2 BR112022010223 A2 BR 112022010223A2 BR 112022010223 A BR112022010223 A BR 112022010223A BR 112022010223 A BR112022010223 A BR 112022010223A BR 112022010223 A2 BR112022010223 A2 BR 112022010223A2
- Authority
- BR
- Brazil
- Prior art keywords
- tslp
- polypeptides
- variable domains
- immunoglobulin variable
- single immunoglobulin
- Prior art date
Links
- 102000003816 Interleukin-13 Human genes 0.000 title abstract 5
- 108090000176 Interleukin-13 Proteins 0.000 title abstract 5
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 3
- 102000018358 immunoglobulin Human genes 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 title 2
- 108010029307 thymic stromal lymphopoietin Proteins 0.000 title 2
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 230000002992 thymic effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
POLIPEPTÍDEOS COMPREENDENDO DOMÍNIOS VARIÁVEIS ÚNICOS DE IMUNOGLOBULINA QUE DIRECIONA INTERLEUCINA 13 (IL-13) E LINFOPOIETINA ESTROMAL TÍMICA (TSLP). A presente invenção refere-se a prover um tipo de fármaco para tratar um indivíduo que está sofrendo de uma doença inflamatória. Especificamente, a presente tecnologia provê polipeptídeos compreendendo pelo menos quatro domínios variáveis únicos de imunoglobulina (ISVDs), caracterizados em que pelo menos dois ISVDs se ligam a IL-13 e pelo menos dois ISVDs se ligam a TSLP. A presente tecnologia também provê ácidos nucleicos, vetores e composições.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945391P | 2019-12-09 | 2019-12-09 | |
| EP20305064 | 2020-01-27 | ||
| PCT/EP2020/085304 WO2021116182A1 (en) | 2019-12-09 | 2020-12-09 | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010223A2 true BR112022010223A2 (pt) | 2022-09-06 |
Family
ID=73793214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010223A BR112022010223A2 (pt) | 2019-12-09 | 2020-12-09 | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina que direcionam interleucina 13 (il-13) e linfopoietina estromal tímica (tslp) |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20210188965A1 (pt) |
| EP (1) | EP4072674A1 (pt) |
| JP (1) | JP2023504914A (pt) |
| KR (1) | KR20220123237A (pt) |
| CN (1) | CN114980974A (pt) |
| AU (1) | AU2020400938A1 (pt) |
| BR (1) | BR112022010223A2 (pt) |
| CA (1) | CA3163910A1 (pt) |
| CO (1) | CO2022008813A2 (pt) |
| IL (1) | IL293548A (pt) |
| MX (1) | MX2022007035A (pt) |
| WO (1) | WO2021116182A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202190162A3 (ru) | 2016-04-27 | 2021-11-30 | Эббви Инк. | Способы лечения заболеваний, при которых активность il-13 оказывает негативное влияние, с применением антител против il-13 |
| MX2023003522A (es) * | 2020-09-25 | 2023-04-19 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l. |
| TW202417502A (zh) * | 2022-07-18 | 2024-05-01 | 比利時商艾伯霖克斯公司 | Cx3cr1結合化合物、方法及其用途 |
| CN118005784A (zh) * | 2022-11-08 | 2024-05-10 | 上海洛启生物医药技术有限公司 | 抗il-13长效纳米抗体序列及其应用 |
| WO2024133935A1 (en) | 2022-12-23 | 2024-06-27 | Ablynx Nv | Protein-based conjugation carriers |
| US20240368250A1 (en) | 2023-02-17 | 2024-11-07 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
| EP4435005A1 (en) | 2023-03-24 | 2024-09-25 | Sanofi | Asthma treatment by blocking il-13 and tslp |
| WO2024200332A1 (en) | 2023-03-24 | 2024-10-03 | Sanofi | Asthma treatment by blocking il-13 and tslp |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE452975T1 (de) | 1992-08-21 | 2010-01-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
| WO2004041865A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Stabilized single domain antibodies |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| MX363423B (es) | 2005-05-18 | 2019-03-22 | Ablynx Nv | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. |
| AU2007237501A1 (en) | 2006-04-14 | 2007-10-25 | Ablynx N.V. | DP-78-like nanobodies |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| AR064333A1 (es) * | 2006-12-14 | 2009-04-01 | Schering Corp | Anticuerpo anti-tslp de diseno |
| PT2723771T (pt) | 2011-06-23 | 2019-12-11 | Ablynx Nv | Proteínas de ligação à albumina sérica |
| DK2723769T4 (da) | 2011-06-23 | 2022-09-05 | Ablynx Nv | Teknikker til at forudsige, påvise og reducere uspecifik proteininterferens i assays, som involverer variable immunglobulin-enkeltdomæner |
| HUE058008T2 (hu) | 2014-05-16 | 2022-06-28 | Ablynx Nv | Immunglobulin variábilis domének |
| US11142569B2 (en) | 2015-11-13 | 2021-10-12 | Ablynx N.V. | Serum albumin-binding immunoglobulin variable domains |
| US10544222B2 (en) * | 2015-11-18 | 2020-01-28 | Merck Sharp & Dohme Corp. | PD1/CTLA4 binders |
| AU2016357460B2 (en) | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
| EP4276114A3 (en) * | 2016-03-07 | 2024-02-21 | Vib Vzw | Cd20 binding single domain antibodies |
| CN110177809B (zh) * | 2016-11-16 | 2023-11-03 | 埃博灵克斯股份有限公司 | 能够结合CD123和TCRα/β的T细胞募集多肽 |
| RU2765384C2 (ru) | 2016-12-07 | 2022-01-28 | Аблинкс Нв | Улучшенные одиночные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином |
| SG10202108973SA (en) | 2017-01-17 | 2021-09-29 | Ablynx Nv | Improved serum albumin binders |
| CA3050575A1 (en) | 2017-01-17 | 2018-07-26 | Ablynx Nv | Improved serum albumin binders |
| KR20210005872A (ko) * | 2018-03-28 | 2021-01-15 | 오리오니스 바이오사이언시즈 인코포레이티드 | 이작용성 단백질 및 이의 작제물 |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
-
2020
- 2020-12-09 BR BR112022010223A patent/BR112022010223A2/pt unknown
- 2020-12-09 CA CA3163910A patent/CA3163910A1/en active Pending
- 2020-12-09 JP JP2022534664A patent/JP2023504914A/ja active Pending
- 2020-12-09 CN CN202080085549.9A patent/CN114980974A/zh active Pending
- 2020-12-09 AU AU2020400938A patent/AU2020400938A1/en active Pending
- 2020-12-09 IL IL293548A patent/IL293548A/en unknown
- 2020-12-09 US US17/115,906 patent/US20210188965A1/en not_active Abandoned
- 2020-12-09 WO PCT/EP2020/085304 patent/WO2021116182A1/en active Application Filing
- 2020-12-09 EP EP20823785.9A patent/EP4072674A1/en active Pending
- 2020-12-09 MX MX2022007035A patent/MX2022007035A/es unknown
- 2020-12-09 KR KR1020227023385A patent/KR20220123237A/ko unknown
-
2021
- 2021-11-19 US US17/530,727 patent/US20220177564A1/en active Pending
- 2021-11-19 US US17/530,850 patent/US20220177566A1/en active Pending
- 2021-11-19 US US17/530,800 patent/US11840566B2/en active Active
-
2022
- 2022-06-24 CO CONC2022/0008813A patent/CO2022008813A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US11840566B2 (en) | 2023-12-12 |
| CA3163910A1 (en) | 2021-06-17 |
| TW202136302A (zh) | 2021-10-01 |
| CN114980974A (zh) | 2022-08-30 |
| US20210188965A1 (en) | 2021-06-24 |
| IL293548A (en) | 2022-08-01 |
| KR20220123237A (ko) | 2022-09-06 |
| JP2023504914A (ja) | 2023-02-07 |
| MX2022007035A (es) | 2022-06-23 |
| US20220177565A1 (en) | 2022-06-09 |
| AU2020400938A1 (en) | 2022-07-28 |
| CO2022008813A2 (es) | 2022-07-19 |
| WO2021116182A1 (en) | 2021-06-17 |
| EP4072674A1 (en) | 2022-10-19 |
| US20220177564A1 (en) | 2022-06-09 |
| US20220177566A1 (en) | 2022-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022010223A2 (pt) | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina que direcionam interleucina 13 (il-13) e linfopoietina estromal tímica (tslp) | |
| Nicolaidou et al. | Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation | |
| AR120698A1 (es) | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp | |
| BR112023005273A2 (pt) | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina direcionados a il-13 e ox40l | |
| BR112022013957A2 (pt) | Inibidores peptídicos do receptor de interleucina-23 e uso dos mesmos para tratar doenças inflamatórias | |
| BRPI0610796B8 (pt) | anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo | |
| Al‐Samadi et al. | IL‐17 C and its receptor IL‐17 RA/IL‐17 RE identify human oral epithelial cell as an inflammatory cell in recurrent aphthous ulcer | |
| CO2021005528A2 (es) | Moléculas de unión a antígeno capaces de unirse al cúmulo de diferenciación 3 (cd3) y al cúmulo de diferenciación 137 (cd137) pero no simultáneamente | |
| MX2022006881A (es) | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina dirigidos a tnf alfa y ox40l. | |
| BR112012028326A2 (pt) | anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos | |
| BR112022000328A2 (pt) | Inibidores peptídicos do receptor de interleucina-23 e seu uso para tratar doenças inflamatórias | |
| BR112022004986A2 (pt) | Anticorpos anti-tnfr2 e métodos de uso | |
| EA201491571A1 (ru) | МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ | |
| PH12017500331A1 (en) | Antigen binding proteins that bind cxcr5 | |
| ZA202107047B (en) | Heterodimeric antibodies that bind enpp3 and cd3 | |
| BR112012018914A2 (pt) | "anticorpo humanizado, proteína de ligação de antígeno, molécula de ácido nucleico, vetor de expressão, célula hospedeira recombinante, proteína de ligação de anticorpo ou de antígeno, métodos para a produção de uma proteína de ligação de antígeno e para tratar um sujeito afetado por uma doença autoimune ou inflamatória, e, composição farmacêutica." | |
| CO2021018192A2 (es) | Composiciones de proteína anti-vegf y métodos para producir la misma | |
| CO2021014153A2 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| MX2018001596A (es) | Anticuerpos anti-receptor ccr7 humanizados. | |
| EA201691782A1 (ru) | Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения | |
| WO2019195623A3 (en) | Heterodimeric antibodies that bind fibroblast activation protein | |
| BR112021018608A2 (pt) | Anticorpos para claudina-6 e conjugados de fármaco | |
| BR112022008092A2 (pt) | Métodos de preparação de uma amostra enriquecida para sequenciamento polipeptídico | |
| BR112022009799A2 (pt) | Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina alvejando tnfalfa e il-23 | |
| ZA202305329B (en) | Multi-specific antibodies and antibody combinations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |